Understanding why certain brain regions are more affected in Lewy Body Dementias
Dissect the mechanisms of selective regional vulnerability in Lewy Body Dementias via comparative snRNA-seq analysis
This study is looking at how certain parts of the brain are affected in Lewy Body Dementias, like Parkinson's disease, to better understand why this happens and how it might help us find new treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11098589 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind the selective vulnerability of specific brain regions in Lewy Body Dementias, such as Parkinson's disease and dementia with Lewy bodies. By utilizing advanced genomic technologies like single nucleus RNA sequencing, the study aims to identify unique cellular populations and their roles in disease progression. The research will analyze how the abnormal aggregation of the protein α-synuclein affects different neurons and brain areas, potentially leading to targeted therapeutic strategies. Patients may benefit from insights into the disease's onset and progression, which could inform future treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Lewy Body Dementias, such as Parkinson's disease or dementia with Lewy bodies.
Not a fit: Patients with other types of neurodegenerative diseases that do not involve Lewy bodies may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients with Lewy Body Dementias.
How similar studies have performed: Previous research has shown promise in understanding neurodegenerative diseases through genomic approaches, indicating potential for success in this novel investigation.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Zhao, Guoyan — Washington University
- Study coordinator: Zhao, Guoyan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.